PDF DatasheetHuman Anti-CD50 / ICAM-3 Antibody Product Attributes
CD50 / ICAM-3 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-ICAM3 antibody staining is expected to be primarily localized to the mitochondria, nuclear membrane and nucleus.
Observed Antibody Staining Data By Tissue Type:
Variations in CD50 / ICAM-3 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in cells in the red pulp in spleen, cells in the white pulp in spleen, epidermal cells in the skin, germinal center cells in the tonsil, hematopoietic cells in the bone marrow, lymphoid tissue in appendix and non-germinal center cells in the lymph node and tonsil. More moderate antibody staining intensity was present in cells in the red pulp in spleen, cells in the white pulp in spleen, epidermal cells in the skin, germinal center cells in the tonsil, hematopoietic cells in the bone marrow, lymphoid tissue in appendix and non-germinal center cells in the lymph node and tonsil. Low, but measureable presence of CD50 / ICAM-3 could be seen in. We were unable to detect CD50 / ICAM-3 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD50 / ICAM-3 expression as measured by anti-CD50 / ICAM-3 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | +++ | – | – | – | – | – | – | – | – | – | – |
| ICAM3 Variability | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | ++ |
| CD50 / ICAM-3 General Information | |
|---|---|
| Alternate Names | |
| Intercellular adhesion molecule 3, ICAM3, CD50, Cluster of Differentiation 50, ICAM-3 | |
| Molecular Weight | |
| 110-160kDa | |
| Chromosomal Location | |
| 19p13.2 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | ICAM3 |
| Entrez Gene ID | 3385 |
| Ensemble Gene ID | ENSG00000076662 |
| RefSeq Protein Accession(s) | NP_001307534, NP_001307537, NP_001307535, NP_002153 |
| RefSeq mRNA Accession(s) | NM_001320606, NM_001320608, NM_002162, NM_001320605 |
| RefSeq Genomic Accession(s) | NC_000019, NC_018930 |
| UniProt ID(s) | A0A024R7C1, K7ERN2, P32942 |
| UniGene ID(s) | A0A024R7C1, K7ERN2, P32942 |
| HGNC ID(s) | 5346 |
| Cosmic ID(s) | ICAM3 |
| KEGG Gene ID(s) | hsa:3385 |
| PharmGKB ID(s) | PA29594 |
| General Description of CD50 / ICAM-3. | |
| Recognizes the D1 domain of an N-glycosylated glycoprotein of 120kDa with intra-chain disulfide bonds, identified as CD50 or ICAM-3. CD50 is the major ligand for LFA-1 (CD11a/CD18), may have signaling role to increase adhesion. It is expressed on thymocytes, T lymphocytes, is resistant to treatment with phosphatidylinositol (PI) phospholipase C. This MAb is excellent for staining of formalin/paraffin tissues. | |
There are no reviews yet.